S

Shanghai MicroPort EP Medtech Co Ltd
SSE:688351

Watchlist Manager
Shanghai MicroPort EP Medtech Co Ltd
SSE:688351
Watchlist
Price: 23.4 CNY 3.13% Market Closed
Market Cap: ¥11B

P/E

162.7
Current
1%
More Expensive
vs 3-y average of 161.3

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
162.7
=
Market Cap
¥10.9B
/
Net Income
¥67.7m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
162.7
=
Market Cap
¥10.9B
/
Net Income
¥67.7m

Valuation Scenarios

Shanghai MicroPort EP Medtech Co Ltd is trading above its 3-year average

If P/E returns to its 3-Year Average (161.3), the stock would be worth ¥23.19 (1% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-82%
Maximum Upside
No Upside Scenarios
Average Downside
42%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 162.7 ¥23.4
0%
3-Year Average 161.3 ¥23.19
-1%
5-Year Average 155.9 ¥22.42
-4%
Industry Average 33.5 ¥4.82
-79%
Country Average 29.6 ¥4.26
-82%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
¥10.9B
/
Jul 2025
¥67.7m
=
162.7
Current
¥10.9B
/
Dec 2025
¥67.3m
=
162.2
Forward
¥10.9B
/
Dec 2026
¥90.3m
=
120.9
Forward
¥10.9B
/
Dec 2027
¥137.8m
=
79.2
Forward
¥10.9B
/
Dec 2028
¥166.4m
=
65.7
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Market Distribution

Higher than 89% of companies in China
Percentile
89th
Based on 5 557 companies
89th percentile
162.7
Low
0 — 17.1
Typical Range
17.1 — 57.7
High
57.7 —
Distribution Statistics
China
Min 0
30th Percentile 17.1
Median 29.6
70th Percentile 57.7
Max 43 569.3

Shanghai MicroPort EP Medtech Co Ltd
Glance View

Market Cap
11B CNY
Industry
Health Care

Shanghai MicroPort EP Medtech Co. Ltd. has carved a distinct niche for itself within the rapidly evolving medical device industry, primarily focusing on electrophysiology. This innovative field deals with diagnosing and treating arrhythmias—irregular heartbeats that affect countless individuals globally. MicroPort EP's flagship products include advanced catheter-based systems and cardiac mapping technologies that physicians utilize to pinpoint and correct these heart rhythm disorders. Their solutions are intricately designed to improve the accuracy and effectiveness of ablation procedures, allowing for non-invasive interventions that can significantly enhance patient outcomes. By capitalizing on the increasing prevalence of cardiovascular ailments and the push towards less invasive medical treatments, the company has positioned itself as a pivotal player in the healthcare sector, gaining a competitive edge with its sophisticated R&D capabilities and product innovation. The company's revenue model revolves around the development, manufacturing, and sales of its proprietary electrophysiology devices. By investing heavily in research and development, MicroPort EP continually advances its product offerings, aiming to stay ahead of its competitors and meet the growing demands of healthcare professionals and patients alike. Sales are driven both domestically, within China's burgeoning healthcare market, and internationally, tapping into the global need for cutting-edge cardiac solutions. The integration of technology and healthcare expertise underscores their commitment to quality and innovation, ensuring a sustainable model as they advance in this niche sector. Ultimately, their financial performance reflects a strategic alignment with health trends and technological progress, allowing them to capture value in a market poised for significant growth.

Intrinsic Value
14.22 CNY
Overvaluation 39%
Intrinsic Value
Price ¥23.4
S
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett